TALS vs. MESO, IBRX, KYMR, BEAM, CGON, TARS, APGE, BCRX, IOVA, and IMCR
Should you be buying Talaris Therapeutics stock or one of its competitors? The main competitors of Talaris Therapeutics include Mesoblast (MESO), ImmunityBio (IBRX), Kymera Therapeutics (KYMR), Beam Therapeutics (BEAM), CG Oncology (CGON), Tarsus Pharmaceuticals (TARS), Apogee Therapeutics (APGE), BioCryst Pharmaceuticals (BCRX), Iovance Biotherapeutics (IOVA), and Immunocore (IMCR). These companies are all part of the "biological products, except diagnostic" industry.
Talaris Therapeutics vs.
Mesoblast (NASDAQ:MESO) and Talaris Therapeutics (NASDAQ:TALS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.
Talaris Therapeutics has lower revenue, but higher earnings than Mesoblast.
Mesoblast currently has a consensus target price of $18.00, indicating a potential upside of 9.96%. Given Mesoblast's stronger consensus rating and higher probable upside, analysts clearly believe Mesoblast is more favorable than Talaris Therapeutics.
Mesoblast's return on equity of 0.00% beat Talaris Therapeutics' return on equity.
Mesoblast has a beta of 3.37, suggesting that its share price is 237% more volatile than the S&P 500. Comparatively, Talaris Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500.
1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 67.6% of Talaris Therapeutics shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 16.5% of Talaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Mesoblast received 399 more outperform votes than Talaris Therapeutics when rated by MarketBeat users. Likewise, 70.31% of users gave Mesoblast an outperform vote while only 48.15% of users gave Talaris Therapeutics an outperform vote.
In the previous week, Mesoblast had 3 more articles in the media than Talaris Therapeutics. MarketBeat recorded 3 mentions for Mesoblast and 0 mentions for Talaris Therapeutics. Mesoblast's average media sentiment score of 0.81 beat Talaris Therapeutics' score of 0.00 indicating that Mesoblast is being referred to more favorably in the media.
Summary
Mesoblast beats Talaris Therapeutics on 13 of the 15 factors compared between the two stocks.
Get Talaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talaris Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TALS) was last updated on 2/22/2025 by MarketBeat.com Staff
Free TALS Stock Alerts